Clinical trials: Recurrent Pterygium
Pterygium, Primary
Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia
To evaluate the recurrence and postoperative complications rates after conjunctival autograft surgery using fibrin adhesive for primary pterygium
- Trial name
- NCT00949728
- Testing
- Conjunctival autograft using fibrin glue
- Where
- Brazil
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Hospital de Olhos Sadalla Amin Ghanem
Pterygium, Bevacizumab
Topical Bevacizumab for Preventing Recurrent Pterygium
The purpose of this study is to determine whether bevacizumab eye drop is effective in the treatment of recurrent pterygium.
- Conditions
- Pterygium, Bevacizumab, VEGF, Anti-VEGF
- Trial name
- NCT01311960
- Testing
- bevacizumab eye drop 0.05%, normal saline 0.9%
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Pterygium
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
- Trial name
- NCT01169909
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Pterygium of the Conjunctiva and Cornea
Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.
- Trial name
- NCT01288404
- Testing
- Fluorometholone, Bevacizumab
- Where
- Thailand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ramathibodi Hospital
Pterygium
Determinants of Pterygium Occurrence and Recurrence in a Rural African Population
The aim of the study is to find out why pterygium occurs and recurs in a rural African population. Participants will be interviewed on personal and lifestyle information, family history of pterygium, environmental exposure and…
- Trial name
- NCT00713180
- Testing
- Pterygium excision followed by grafting
- Where
- South Africa
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Anguria, Peter, M.D.
Recurrent Pterygium of Eye, Steroid-Induced Glaucoma
Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium
The objective of this study was to evaluate the efficacy of topical 0.2% loteprednol etabonate, a 'soft steroid', compared with topical 0.1% dexamethasone, which is widely used in postoperative pterygium excision to prevent the…
- Trial name
- NCT04075227
- Testing
- 0.2% loteprednol etabonate, 0.1% dexamethasone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Wannisa Suphachearabhan
Recurrent Pterygia
Amniotic Membrane Associated With Conjunctival Autograft Versus Conjunctival Autograft for Recurrent Pterygia
The purpose of this study is to compare amniotic membrane associated with conjunctival autograft versus conjunctival autograft alone in the treatment of recurrent pterygia.
- Trial name
- NCT00802620
- Testing
- Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Pterygium of Conjunctiva and Cornea
Recurrence Rate of Mini-SLET vs. Limbal-Conjunctival Autograft in Primary Pterygium Excision
To study the efficacy and safety of amniotic membrane transplantation as an adjunctive therapy after surgical excision of primary pterygium and compare the clinical outcomes with conjunctival autograft
- Trial name
- NCT03363282
- Testing
- Pterygium Excision
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Patients With Primary Nasal Pterygium
Effects of Ranibizumab in Primary Pterygium Surgery
Pterygium is a common ocular surface disease in Malaysia. Without treatment, it can lead to severe visual impairment. Recurrence is the commonest complication and novel treatment approaches are crucial to prevent vision loss.
- Trial name
- NCT04878835
- Testing
- intralesional ranibizumab
- Where
- Malaysia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Universiti Sains Malaysia